tadalafil has been researched along with Urinary Tract Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukagai, T; Hayashi, K; Hirayama, K; Igarashi, A; Ishikawa, K; Koshikiya, A; Morita, M; Noguchi, T; Ogawa, Y; Sasaki, H | 1 |
| Ashitomi, K; Kadekawa, K; Nishijima, S; Sugaya, K; Ueda, T; Yamamoto, H | 1 |
| Dong, Y; Han, C; Hao, L; Shi, Z; Wang, G; Zhang, Z | 1 |
| Belgrano, E; Bucci, S; De Giorgi, G; Liguori, G; Maio, G; Ocello, G; Ollandini, G; Pomara, G; Trombetta, C; Vecchio, D | 1 |
| Andersson, KE; de Groat, WC; Lue, TF; Maggi, M; McVary, KT; Melby, T; Roehrborn, CG; Viktrup, L; Wyndaele, JJ | 1 |
| Gonzalez, RR; Kaplan, SA | 1 |
3 review(s) available for tadalafil and Urinary Tract Diseases
| Article | Year |
|---|---|
Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis.
Topics: Carbolines; Erectile Dysfunction; Humans; Male; Patient Safety; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Risk; Tadalafil; Treatment Outcome; Urinary Tract; Urologic Diseases; Urological Agents | 2013 |
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Topics: Carbolines; Evidence-Based Medicine; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Recovery of Function; Signal Transduction; Tadalafil; Treatment Outcome; Urodynamics; Urologic Diseases | 2011 |
Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Humans; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Prostatic Hyperplasia; Tadalafil; Urologic Diseases | 2006 |
1 trial(s) available for tadalafil and Urinary Tract Diseases
| Article | Year |
|---|---|
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Aged; Carbolines; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Quinazolines; Tadalafil; Treatment Outcome; Urologic Diseases | 2009 |
2 other study(ies) available for tadalafil and Urinary Tract Diseases
| Article | Year |
|---|---|
[EFFECTIVENESS AND SAFETY OF TADALAFIL IN VERY ELDERLY PATIENTS WITH LOWER URINARY TRACT SYMPTOMS].
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Patient Safety; Phosphodiesterase 5 Inhibitors; Tadalafil; Treatment Outcome; Urologic Diseases | 2019 |
Tadalafil improves bladder dysfunction and object recognition in rats with pelvic venous congestion.
Topics: Animals; Disease Models, Animal; Female; Hyperemia; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tadalafil; Urinary Bladder; Urination; Urologic Diseases; Urological Agents | 2019 |